Sugi Predict

Sugi Predict / Compounds / SCHEMBL4664040

SCHEMBL4664040

SCHEMBL4664040

CC(=O)NCc1cc(C)no1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 4/20 0.56
▸ EPHX2 P34913 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ VHL P40337 1/20 0.51
▸ USP2 O75604 1/20 0.48
▸ HCAR2 Q8TDS4 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ PDE10A Q9Y233 1/20 0.42
▸ NAMPT P43490 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NR3C2 P08235 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4204403 0.87 EPHX2 (0.57) POLBEPHX2SMN1; SMN2CYP1A2VHL
SCHEMBL21023373 0.81 LMNA (0.59) POLBEPHX2SMN1; SMN2VHLUSP2
SCHEMBL17689399 0.78 POLB (0.52) POLBEPHX2SMN1; SMN2CYP1A2ALDH1A1
SCHEMBL11925373 0.78 SMN1; SMN2 (0.64) POLBSMN1; SMN2CYP1A2ALDH1A1NPSR1
SCHEMBL6403162 0.78 POLB (0.54) POLBEPHX2SMN1; SMN2CYP1A2USP2
SCHEMBL8235172 0.78 EPHX2 (0.49) POLBEPHX2SMN1; SMN2CYP1A2VHL
SCHEMBL18031837 0.76 POLB (0.50) POLBEPHX2SMN1; SMN2CYP1A2ALDH1A1
SCHEMBL4093165 0.76 VHL (0.60) POLBEPHX2SMN1; SMN2VHLUSP2
SCHEMBL81734 0.75 — —
SCHEMBL16656012 0.75 EPHX2 (0.55) POLBEPHX2SMN1; SMN2CYP1A2VHL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022261524-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2, COMPOSITION AND APPLICATION THEREOF ACCRO BIOSCIENCE (HK) LIMITED (CN) 2022-12-15 — — WO disclosed
US-20210171475-A1 COMPOUNDS UCL BUSINESS LTD (GB) 2021-06-10 — — US disclosed
WO-2020043866-A1 COMPOUNDS UCL BUSINESS LTD (GB) 2020-03-05 — — WO disclosed
WO-2019079469-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2019-04-25 — — WO disclosed
EP-2994469-B1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES INC (US) 2018-12-19 — — EP disclosed
US-20180282316-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. 2018-10-04 — — US disclosed
US-10017501-B2 Benzimidazole derivatives as bromodomain inhibitors GILEAD SCIENCES, INC. (US) 2018-07-10 — — US disclosed
US-10017501-B2 Benzimidazole derivatives as bromodomain inhibitors GILEAD SCIENCES, INC. (US) 2018-07-10 — — US disclosed
US-20160376261-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. 2016-12-29 — — US disclosed
US-9458145-B2 Benzimidazole derivatives as bromodomain inhibitors GILEAD SCIENCES, INC. (US) 2016-10-04 — — US disclosed
US-9458145-B2 Benzimidazole derivatives as bromodomain inhibitors GILEAD SCIENCES, INC. (US) 2016-10-04 — — US disclosed
US-20160075695-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. (US) 2016-03-17 — — US disclosed
EP-2994469-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS Gilead Sciences, Inc. (US) 2016-03-16 — — EP disclosed
US-20140336190-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. (US) 2014-11-13 — — US disclosed
US-20140336190-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. (US) 2014-11-13 — — US disclosed
WO-2014182929-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. (US) 2014-11-13 — — WO disclosed
WO-2014182929-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. (US) 2014-11-13 — — WO disclosed
EP-2007717-A1 NOVEL SULFONAMIDE COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2008-12-31 — — EP disclosed
WO-2007116374-A1 NOVEL SULFONAMIDE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282316-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 POLB 304/4885EPHX2 4455/4885SMN1; SMN2 3348/4885
US-20210171475-A1 COMPOUNDS GOT2, GOT1, OAT POLB 1592/4885EPHX2 2854/4885SMN1; SMN2 74/4885
US-10017501-B2 Benzimidazole derivatives as bromodomain inhibitors BRD4, BRD3, BRD1 POLB 304/4885EPHX2 4455/4885SMN1; SMN2 3348/4885
US-20160075695-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 POLB 266/4885EPHX2 4415/4885SMN1; SMN2 3400/4885
US-20160376261-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 POLB 304/4885EPHX2 4455/4885SMN1; SMN2 3348/4885
US-20140336190-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 POLB 287/4885EPHX2 4483/4885SMN1; SMN2 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.